Showing results (91-100 of 115) with videos related to

Sort By:
Pageof 12
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 10, 2014
Cranberry versus placebo in the prevention of urinary infections in multiple sclerosis: a multicenter, randomized, placebo-controlled, double-blind trialPhilippe Gallien, Gérard Amarenco, Nicolas Benoit, et al.
International Journal of MS Care|January 24, 2014
Development and validation of the actionable bladder symptom screening tool for multiple sclerosis patientsJack Burks, Michael Chancellor, David Bates, et al.
European Urology|November 1, 2011
Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging studyPierre Denys, Loïc Le Normand, Idir Ghout, et al.
European Urology Focus|March 21, 2020
Nocturia and Nocturnal Polyuria in Neurological Patients: From Epidemiology to Treatment. A Systematic Review of the LiteratureRebecca Haddad, Pierre Denys, Salvador Arlandis, et al.
Toxins|December 24, 2015
Does Reduction of Number of Intradetrusor Injection Sites of aboBoNTA (Dysport®) Impact Efficacy and Safety in a Rat Model of Neurogenic Detrusor Overactivity?Amélie Huynh Le Maux, Bernadette Pignol, Delphine Behr-Roussel, et al.
The Journal of Urology|June 11, 2005
Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month studyBrigitte Schurch, Marianne de Sèze, Pierre Denys, et al.
Neurourology and Urodynamics|September 21, 2006
Intravesical glucidic capsaicin versus glucidic solvent in neurogenic detrusor overactivity: a double blind controlled randomized studyMarianne de Sèze, Philippe Gallien, Pierre Denys, et al.
Antimicrobial Agents and Chemotherapy|April 28, 2005
Spread of a Klebsiella pneumoniae strain producing a plasmid-mediated ACC-1 AmpC beta-lactamase in a teaching hospital admitting disabled patientsSalomon Ohana, Veronique Leflon, Esthel Ronco, et al.
Neurourology and Urodynamics|July 27, 2017
Long-term outcomes and risks factors for failure of intradetrusor onabotulinumtoxin A injections for the treatment of refractory neurogenic detrusor overactivityCharles Joussain, Mélanie Popoff, Véronique Phé, et al.
European Journal of Neurology|December 20, 2024
Hereditary spastic paraplegias: When to expect bladder dysfunction a genetic and urodynamic studyPauline Lallemant-Dudek, Marine Guillaud-Bataille, Claire Hentzen, et al.
Pageof 12